Drospirenone, Ethinyl Estradiol And Levomefolate Calcium And Levomefolate Calcium Kit
Product Images NDC 68180-894

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Drospirenone, Ethinyl Estradiol And Levomefolate Calcium And Levomefolate Calcium (NDC 68180-894). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Ec8fe00a Ff36 4936 Aaef 4cd5e722d4fc 134 2)

Chemical structure of drospirenone depicted as a complex steroidal framework with multiple rings and functional groups, including ketone and lactone moieties.*

FDA Label Image

Image (Ec8fe00a Ff36 4936 Aaef 4cd5e722d4fc 134 3)

Chemical structure of the active ingredient, likely related to drospirenone or ethinyl estradiol, displayed as a molecular diagram showing its atomic connectivity and bond arrangement.*

FDA Label Image

Image (Ec8fe00a Ff36 4936 Aaef 4cd5e722d4fc 134 4)

Chemical structure of levomefolate calcium, showing its molecular connectivity and arrangement. The image is a structural diagram depicting atoms and bonds characteristic of this active ingredient.*

FDA Label Image

Image-01 (Ec8fe00a Ff36 4936 Aaef 4cd5e722d4fc 59)

A forest plot comparing hazard ratios, rate ratios, and odds ratios from multiple studies including Ingerix, EURAS, LASS, FDA-funded, Danish, MEGA, German case-control, PharMetrics, and GPRD. Studies are categorized into prospective cohort, retrospective cohort, case-control, and non-fatal idiopathic groups. The plot visualizes point estimates with confidence intervals on a logarithmic scale axis from 0.1 to 10.*

FDA Label Image

Image-02 (Ec8fe00a Ff36 4936 Aaef 4cd5e722d4fc 60)

A horizontal bar chart showing the number of women with a blood clot per 10,000 women years (WY) across four groups: Non-Pregnant Non-COC users (ranges 1 to 5), COC users (ranges 3 to 9), Pregnancy (ranges 5 to 20), and Postpartum (12 weeks only) with the highest range from 40 to 65. The pregnancy data is noted to be based on actual duration of pregnancy in reference studies, with a model assumption rate for pregnancy duration less than nine months.*

FDA Label Image

Image (Ec8fe00a Ff36 4936 Aaef 4cd5e722d4fc 61)

A forest plot chart comparing effect estimates for combined oral contraceptive (COC) use versus never use across multiple studies. The vertical axis lists studies by name and year, while the horizontal axis shows effect estimates ranging from -1.5 to 2.0. Data points with confidence intervals illustrate odds ratios (OR), relative risks (RR), and hazard ratios (HR) with values and ranges for each study.*

FDA Label Image

Image-03 (Ec8fe00a Ff36 4936 Aaef 4cd5e722d4fc 62)

A line graph comparing plasma folate levels (nmol/L) over 24 weeks between two groups: YAZ plus levomefolate calcium (N=196) and YAZ alone (N=66). The x-axis represents time in weeks, including a pre-treatment point, while the y-axis shows plasma folate concentration. Data include mean values with error bars indicating variability.*

FDA Label Image

Image (Ec8fe00a Ff36 4936 Aaef 4cd5e722d4fc 63)

A line graph comparing red blood cell (RBC) folate levels over 24 weeks between two groups: YAZ plus levomefolate calcium and YAZ alone. The x-axis shows time in weeks, and the y-axis shows RBC folate concentration in nmol/L. Data includes error bars representing variability.*

FDA Label Image

Image (Ec8fe00a Ff36 4936 Aaef 4cd5e722d4fc 64)

A line chart showing plasma folates (nmol/L) over time in weeks from pre-treatment through a 24-week treatment phase and a 20-week elimination phase. The data represent Yasmin + levomefolate calcium for 75 subjects, with error bars indicating variability at each time point.*

FDA Label Image

Image-06 (Ec8fe00a Ff36 4936 Aaef 4cd5e722d4fc 65)

A line graph showing RBC (red blood cell) totals over time (weeks) comparing treatment and elimination phases for Yasmin plus levomefolate calcium (N=75). The y-axis represents RBC totals (x10^6/µL), and the x-axis shows time in weeks from pre-treatment through 44 weeks. Data points include error bars indicating variability.*

FDA Label Image

Image-07 (Ec8fe00a Ff36 4936 Aaef 4cd5e722d4fc 66)

An illustrative diagram showing various birth control methods arranged vertically along an arrow labeled from 'Fewer Pregnancies' at the top to 'More Pregnancies' at the bottom, with corresponding pregnancy rates per 100 women per year. Methods with fewer pregnancies include implants, injections, intrauterine devices, and sterilization, followed by birth control pills, skin patch, vaginal ring with hormones, condoms, and diaphragm. Methods listed with higher pregnancies include no sex during fertile days, spermicide, withdrawal, and no birth control.*

FDA Label Image

Figure-08 (Ec8fe00a Ff36 4936 Aaef 4cd5e722d4fc 67)

An illustrated weekly dosing calendar for Drospirenone, Ethinyl Estradiol, and Levomefolate Calcium tablets by Lupin Pharmaceuticals. It shows four rows labeled Week 1 to Week 4 with days of the week from Sunday to Saturday. Circular day markers are arranged for tracking daily tablet intake, with arrows indicating the sequence. Instructions for starting the medication on a day other than Sunday and a note about monthly self breast exam are included. Storage conditions are noted at the bottom.*

FDA Label Image

Image-09 (Ec8fe00a Ff36 4936 Aaef 4cd5e722d4fc 68)

A horizontal bar chart showing the number of women who experience blood clots per 10,000 women years. Categories include Non-Pregnant Non-COC users (1 to 5), COC-Users (3 to 9), Pregnancy (5 to 20), and Postpartum (12 weeks only) with the highest range (40 to 65).*

FDA Label Image

Image-10 (Ec8fe00a Ff36 4936 Aaef 4cd5e722d4fc 69)

Packaging label for Drospirenone, Ethinyl Estradiol and Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg, by Lupin Pharmaceuticals, Inc. The label shows product details including dosage strengths, quantity of 3 wallets of 28 tablets each, prescription only status, and includes barcodes and manufacturer information.*

FDA Label Image

Image-11 (Ec8fe00a Ff36 4936 Aaef 4cd5e722d4fc 70)

Packaging label for Drospirenone, Ethinyl Estradiol and Levomefolate Calcium Tablets and Levomefolate Calcium Tablets. The label shows strengths of 3 mg, 0.02 mg, 0.451 mg, and 0.451 mg respectively. The product is distributed by Lupin Pharmaceuticals, Inc. and comes as a wallet containing 28 tablets. The label also includes NDC 68180-894-11 and barcode images.*

FDA Label Image

Image-12 (Ec8fe00a Ff36 4936 Aaef 4cd5e722d4fc 71)

Packaging label for Drospirenone, Ethinyl Estradiol and Levomefolate Calcium Tablets by Lupin Pharmaceuticals, Inc. It includes directions for weekly dosing over 4 weeks, space for pharmacy label, and storage instructions at 25°C (77°F). The strength is 3 mg/0.02 mg/4.51 mg and the package contains 28 tablets. Distributed by Lupin Pharmaceuticals, Inc. with NDC 68180-894.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.